- Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
- Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
- Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals Inc (HDP1:BER) closed at 34.59, 31.47% above the 52 week low of 26.31 set on Jun 17, 2022.
26.31Jun 17 202270.48Nov 09 2021
Markit short selling activity
|Market cap||3.14bn USD|
|EPS (TTM)||-1.48 |
Data delayed at least 15 minutes, as of Oct 05 2022 07:08 BST.